Abstract | BACKGROUND: METHODS: RESULTS: Out of the 43 cases enrolled in this study, 38 completed the 28-day follow-up. Their mean age was 25.1 years (SD: 1.5). On day 3 following AL treatment, all of the patients were afebrile and aparasitaemic. By day 28, all 38 patients exhibited adequate clinical and parasitological responses to AL treatment. The cure rate was 100% and 88.4% for the per protocol analysis andfor the intention to treat analysis, respectively. Mild adverse effects ( nausea, vomiting, abdominal pain, dizziness and/or rash) that resolved spontaneously were observed in four (10.5%) of the patients. CONCLUSION: AL combination therapy was fully effective for treatment of P. vivax malaria in the study in eastern Sudan. TRIAL REGISTRATION: Trial. Gov: NCT01625871.
|
Authors | Tajeldin M Abdallah, Abdel Aziem A Ali, Mohammed Bakri, Gasim I Gasim, Imad R Musa, Ishag Adam |
Journal | Malaria journal
(Malar J)
Vol. 11
Pg. 404
(Dec 05 2012)
ISSN: 1475-2875 [Electronic] England |
PMID | 23217037
(Publication Type: Journal Article)
|
Chemical References |
- Antimalarials
- Artemether, Lumefantrine Drug Combination
- Artemisinins
- Drug Combinations
- Ethanolamines
- Fluorenes
|
Topics |
- Adolescent
- Adult
- Antimalarials
(administration & dosage)
- Artemether, Lumefantrine Drug Combination
- Artemisinins
(administration & dosage)
- Child
- Child, Preschool
- Drug Combinations
- Ethanolamines
(administration & dosage)
- Female
- Fluorenes
(administration & dosage)
- Humans
- Malaria, Vivax
(drug therapy)
- Male
- Middle Aged
- Plasmodium vivax
(drug effects)
- Sudan
- Treatment Outcome
- Young Adult
|